Drug General Information (ID: DDI5NLVT3M)
Drug Name			Ticlopidine		Drug Info		Acetylsalicylic acid		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Fibrinolytic Agents				Analgesics
Structure

Mechanism of Ticlopidine-Acetylsalicylic acid Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Ticlopidine				Acetylsalicylic acid
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Ticlopidine and Acetylsalicylic acid

Recommended Action
Management		The safety of concomitant use of ticlopidine with aspirin or other platelet-inhibiting salicylates has not been established. Ticlopidine labeling recommends against long-term coadministration with aspirin. However, ticlopidine (250 mg twice daily) may be given with antiplatelet dosages of aspirin for up to 30 days following successful coronary artery stent implantation to reduce the risk of blood clots forming inside the stent. Close monitoring for bleeding complications, particularly GI bleeding, is advised during treatment.

References
1	Product Information. Ticlid (ticlopidine). Syntex Laboratories Inc, Palo Alto, CA.
2	Ranhosky A, Kempthorne-Rawson J, the Intravenous Dipyridamole Thallium Imaging Study Group "The safety of intravenous dipyridamole thallium myocardial perfusion imaging." Circulation 81 (1990): 1205-9. [PMID: 2107985]